German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)
Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options...
Gespeichert in:
| Veröffentlicht in: | Archives of Dermatological Research 2007-06, Vol.299 (3), p.111-138 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 3 |
| container_start_page | 111 |
| container_title | Archives of Dermatological Research |
| container_volume | 299 |
| creator | NAST, A KOPP, I KOZA, J KREISELMAIER, I MOHR, J MROWIETZ, U OCKENFELS, H. M ORZECHOWSKI, H. D PRINZ, J REICH, K ROSENBACH, T ROSUMECK, S AUGUSTIN, M SCHLAEGER, M SCHMID-OTT, G SEBASTIAN, M STREIT, V WEBERSCHOCK, T RZANY, B BANDITT, K. B BOEHNCKE, W. H FOLLMANN, M FRIEDRICH, M HUBER, M KAHL, C KLAUS, J |
| description | Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de ). |
| doi_str_mv | 10.1007/s00403-007-0744-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1910890</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1278749061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-659e74222ed234837547a3185e7d4ed175ed5fafa15e7d62b8f16d0343b5a243</originalsourceid><addsrcrecordid>eNpVUU1rGzEUFCWhNkl-QC9FFALNQcnTx0q7l0AJjRMIJIccfBPy7ltbZr1KpV2D_31lbPKhyxs9zRuNNIT84HDNAcxNAlAgWYYMjFJs941MuZKCga7mJ2QKUgGTutITcpHSGvIyoASY72TCjaoM12JK5jOMG9dT3PoG-xrZwiVs6HLM2873mGgbIh1WSIeIbthgP9DQ0pcUonfJJ7odu6WLGfxOqxAHusWYfOivzslp67qEF8d6Rl7v_77ePbCn59nj3Z8nVqtCDUwXFRolhMBGSFVKUyjjJC8LNI3ChpsCm6J1reP7jhaLsuW6yW-Ti8IJJc_I7UH2bVxssKmzv-g6-xb9xsWdDc7brye9X9ll2FpecSgryAK_jgIx_BsxDXYdxthny1bw7KsALTKJH0h1DClFbN8v4GD3adhDGnYP92nYXZ75-dnZx8Tx7zPh8khwqXZdG11f-_TBK0uuqkrL_2zSk4Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212225062</pqid></control><display><type>article</type><title>German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>NAST, A ; KOPP, I ; KOZA, J ; KREISELMAIER, I ; MOHR, J ; MROWIETZ, U ; OCKENFELS, H. M ; ORZECHOWSKI, H. D ; PRINZ, J ; REICH, K ; ROSENBACH, T ; ROSUMECK, S ; AUGUSTIN, M ; SCHLAEGER, M ; SCHMID-OTT, G ; SEBASTIAN, M ; STREIT, V ; WEBERSCHOCK, T ; RZANY, B ; BANDITT, K. B ; BOEHNCKE, W. H ; FOLLMANN, M ; FRIEDRICH, M ; HUBER, M ; KAHL, C ; KLAUS, J</creator><creatorcontrib>NAST, A ; KOPP, I ; KOZA, J ; KREISELMAIER, I ; MOHR, J ; MROWIETZ, U ; OCKENFELS, H. M ; ORZECHOWSKI, H. D ; PRINZ, J ; REICH, K ; ROSENBACH, T ; ROSUMECK, S ; AUGUSTIN, M ; SCHLAEGER, M ; SCHMID-OTT, G ; SEBASTIAN, M ; STREIT, V ; WEBERSCHOCK, T ; RZANY, B ; BANDITT, K. B ; BOEHNCKE, W. H ; FOLLMANN, M ; FRIEDRICH, M ; HUBER, M ; KAHL, C ; KLAUS, J</creatorcontrib><description>Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de ).</description><identifier>ISSN: 0340-3696</identifier><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-007-0744-y</identifier><identifier>PMID: 17497162</identifier><identifier>CODEN: ADREDL</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Biological and medical sciences ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - adverse effects ; Dermatologic Agents - therapeutic use ; Dermatology ; Evidence-Based Medicine ; Germany ; Humans ; Medical sciences ; Psoriasis - drug therapy ; Psoriasis - physiopathology ; Psoriasis. Parapsoriasis. Lichen ; Review ; Severity of Illness Index</subject><ispartof>Archives of Dermatological Research, 2007-06, Vol.299 (3), p.111-138</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-659e74222ed234837547a3185e7d4ed175ed5fafa15e7d62b8f16d0343b5a243</citedby><cites>FETCH-LOGICAL-c454t-659e74222ed234837547a3185e7d4ed175ed5fafa15e7d62b8f16d0343b5a243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18814996$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17497162$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NAST, A</creatorcontrib><creatorcontrib>KOPP, I</creatorcontrib><creatorcontrib>KOZA, J</creatorcontrib><creatorcontrib>KREISELMAIER, I</creatorcontrib><creatorcontrib>MOHR, J</creatorcontrib><creatorcontrib>MROWIETZ, U</creatorcontrib><creatorcontrib>OCKENFELS, H. M</creatorcontrib><creatorcontrib>ORZECHOWSKI, H. D</creatorcontrib><creatorcontrib>PRINZ, J</creatorcontrib><creatorcontrib>REICH, K</creatorcontrib><creatorcontrib>ROSENBACH, T</creatorcontrib><creatorcontrib>ROSUMECK, S</creatorcontrib><creatorcontrib>AUGUSTIN, M</creatorcontrib><creatorcontrib>SCHLAEGER, M</creatorcontrib><creatorcontrib>SCHMID-OTT, G</creatorcontrib><creatorcontrib>SEBASTIAN, M</creatorcontrib><creatorcontrib>STREIT, V</creatorcontrib><creatorcontrib>WEBERSCHOCK, T</creatorcontrib><creatorcontrib>RZANY, B</creatorcontrib><creatorcontrib>BANDITT, K. B</creatorcontrib><creatorcontrib>BOEHNCKE, W. H</creatorcontrib><creatorcontrib>FOLLMANN, M</creatorcontrib><creatorcontrib>FRIEDRICH, M</creatorcontrib><creatorcontrib>HUBER, M</creatorcontrib><creatorcontrib>KAHL, C</creatorcontrib><creatorcontrib>KLAUS, J</creatorcontrib><title>German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)</title><title>Archives of Dermatological Research</title><addtitle>Arch Dermatol Res</addtitle><description>Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de ).</description><subject>Biological and medical sciences</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Dermatology</subject><subject>Evidence-Based Medicine</subject><subject>Germany</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - physiopathology</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Review</subject><subject>Severity of Illness Index</subject><issn>0340-3696</issn><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVUU1rGzEUFCWhNkl-QC9FFALNQcnTx0q7l0AJjRMIJIccfBPy7ltbZr1KpV2D_31lbPKhyxs9zRuNNIT84HDNAcxNAlAgWYYMjFJs941MuZKCga7mJ2QKUgGTutITcpHSGvIyoASY72TCjaoM12JK5jOMG9dT3PoG-xrZwiVs6HLM2873mGgbIh1WSIeIbthgP9DQ0pcUonfJJ7odu6WLGfxOqxAHusWYfOivzslp67qEF8d6Rl7v_77ePbCn59nj3Z8nVqtCDUwXFRolhMBGSFVKUyjjJC8LNI3ChpsCm6J1reP7jhaLsuW6yW-Ti8IJJc_I7UH2bVxssKmzv-g6-xb9xsWdDc7brye9X9ll2FpecSgryAK_jgIx_BsxDXYdxthny1bw7KsALTKJH0h1DClFbN8v4GD3adhDGnYP92nYXZ75-dnZx8Tx7zPh8khwqXZdG11f-_TBK0uuqkrL_2zSk4Y</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>NAST, A</creator><creator>KOPP, I</creator><creator>KOZA, J</creator><creator>KREISELMAIER, I</creator><creator>MOHR, J</creator><creator>MROWIETZ, U</creator><creator>OCKENFELS, H. M</creator><creator>ORZECHOWSKI, H. D</creator><creator>PRINZ, J</creator><creator>REICH, K</creator><creator>ROSENBACH, T</creator><creator>ROSUMECK, S</creator><creator>AUGUSTIN, M</creator><creator>SCHLAEGER, M</creator><creator>SCHMID-OTT, G</creator><creator>SEBASTIAN, M</creator><creator>STREIT, V</creator><creator>WEBERSCHOCK, T</creator><creator>RZANY, B</creator><creator>BANDITT, K. B</creator><creator>BOEHNCKE, W. H</creator><creator>FOLLMANN, M</creator><creator>FRIEDRICH, M</creator><creator>HUBER, M</creator><creator>KAHL, C</creator><creator>KLAUS, J</creator><general>Springer</general><general>Springer Nature B.V</general><general>Springer-Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20070601</creationdate><title>German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)</title><author>NAST, A ; KOPP, I ; KOZA, J ; KREISELMAIER, I ; MOHR, J ; MROWIETZ, U ; OCKENFELS, H. M ; ORZECHOWSKI, H. D ; PRINZ, J ; REICH, K ; ROSENBACH, T ; ROSUMECK, S ; AUGUSTIN, M ; SCHLAEGER, M ; SCHMID-OTT, G ; SEBASTIAN, M ; STREIT, V ; WEBERSCHOCK, T ; RZANY, B ; BANDITT, K. B ; BOEHNCKE, W. H ; FOLLMANN, M ; FRIEDRICH, M ; HUBER, M ; KAHL, C ; KLAUS, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-659e74222ed234837547a3185e7d4ed175ed5fafa15e7d62b8f16d0343b5a243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Dermatology</topic><topic>Evidence-Based Medicine</topic><topic>Germany</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - physiopathology</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Review</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NAST, A</creatorcontrib><creatorcontrib>KOPP, I</creatorcontrib><creatorcontrib>KOZA, J</creatorcontrib><creatorcontrib>KREISELMAIER, I</creatorcontrib><creatorcontrib>MOHR, J</creatorcontrib><creatorcontrib>MROWIETZ, U</creatorcontrib><creatorcontrib>OCKENFELS, H. M</creatorcontrib><creatorcontrib>ORZECHOWSKI, H. D</creatorcontrib><creatorcontrib>PRINZ, J</creatorcontrib><creatorcontrib>REICH, K</creatorcontrib><creatorcontrib>ROSENBACH, T</creatorcontrib><creatorcontrib>ROSUMECK, S</creatorcontrib><creatorcontrib>AUGUSTIN, M</creatorcontrib><creatorcontrib>SCHLAEGER, M</creatorcontrib><creatorcontrib>SCHMID-OTT, G</creatorcontrib><creatorcontrib>SEBASTIAN, M</creatorcontrib><creatorcontrib>STREIT, V</creatorcontrib><creatorcontrib>WEBERSCHOCK, T</creatorcontrib><creatorcontrib>RZANY, B</creatorcontrib><creatorcontrib>BANDITT, K. B</creatorcontrib><creatorcontrib>BOEHNCKE, W. H</creatorcontrib><creatorcontrib>FOLLMANN, M</creatorcontrib><creatorcontrib>FRIEDRICH, M</creatorcontrib><creatorcontrib>HUBER, M</creatorcontrib><creatorcontrib>KAHL, C</creatorcontrib><creatorcontrib>KLAUS, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of Dermatological Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NAST, A</au><au>KOPP, I</au><au>KOZA, J</au><au>KREISELMAIER, I</au><au>MOHR, J</au><au>MROWIETZ, U</au><au>OCKENFELS, H. M</au><au>ORZECHOWSKI, H. D</au><au>PRINZ, J</au><au>REICH, K</au><au>ROSENBACH, T</au><au>ROSUMECK, S</au><au>AUGUSTIN, M</au><au>SCHLAEGER, M</au><au>SCHMID-OTT, G</au><au>SEBASTIAN, M</au><au>STREIT, V</au><au>WEBERSCHOCK, T</au><au>RZANY, B</au><au>BANDITT, K. B</au><au>BOEHNCKE, W. H</au><au>FOLLMANN, M</au><au>FRIEDRICH, M</au><au>HUBER, M</au><au>KAHL, C</au><au>KLAUS, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)</atitle><jtitle>Archives of Dermatological Research</jtitle><addtitle>Arch Dermatol Res</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>299</volume><issue>3</issue><spage>111</spage><epage>138</epage><pages>111-138</pages><issn>0340-3696</issn><eissn>1432-069X</eissn><coden>ADREDL</coden><abstract>Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de ).</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>17497162</pmid><doi>10.1007/s00403-007-0744-y</doi><tpages>28</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-3696 |
| ispartof | Archives of Dermatological Research, 2007-06, Vol.299 (3), p.111-138 |
| issn | 0340-3696 1432-069X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1910890 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biological and medical sciences Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Dermatology Evidence-Based Medicine Germany Humans Medical sciences Psoriasis - drug therapy Psoriasis - physiopathology Psoriasis. Parapsoriasis. Lichen Review Severity of Illness Index |
| title | German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A21%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=German%20evidence-based%20guidelines%20for%20the%20treatment%20of%20Psoriasis%20vulgaris%20(short%20version)&rft.jtitle=Archives%20of%20Dermatological%20Research&rft.au=NAST,%20A&rft.date=2007-06-01&rft.volume=299&rft.issue=3&rft.spage=111&rft.epage=138&rft.pages=111-138&rft.issn=0340-3696&rft.eissn=1432-069X&rft.coden=ADREDL&rft_id=info:doi/10.1007/s00403-007-0744-y&rft_dat=%3Cproquest_pubme%3E1278749061%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212225062&rft_id=info:pmid/17497162&rfr_iscdi=true |